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ProliferationBCR-ABL kinase activates downstream signaling pathways, including the PI3K-Akt/mTOR and the MAPK
pathway. IRS1 has been previously described as constitutively phosphorylated and associated with BCR-ABL
in K562 cells, suggesting that IRS1 has role in the BCR-ABL signaling pathways. In this study, we analyzed the
effect of IRS1 silencing, by shRNA-lentiviral delivery, in K562 cells, a CML cell line that presents the BCR-ABL.
IRS1 silencing decreased cell proliferation and colony formation in K562 cells, which correlates with the delay
of these cells at the G0/G1 phase and a decrease in the S phase of the cell cycle. Furthermore, IRS1 silencing in
K562 cells resulted in a decrease of Akt, P70S6K and ERK1/2 phosphorylation. Nevertheless, apoptosis was
unaffected by IRS1 knockdown and no alterations were found in the phosphorylation of BAD and in the
expression of BCL2 and BAX. BCR-ABL and CRKL phosphorylation levels remained unaffected upon IRS1
silencing, and no synergistic effect was observed with imatinib treatment and IRS1 knockdown, indicating
that IRS1 is downstream from BCR-ABL. In conclusion, we demonstrated that inhibition of IRS1 is capable of
inducing the downregulation of Akt/mTOR and MAPK pathways and further decreasing proliferation, and
clonogenicity and induces to cell cycle delay at G0/G1 phase in BCR-ABL cells.Rua Carlos Chagas, 480, CEP
4; fax: +55 19 3289 1089.
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The signaling network controlled by the breakpoint cluster region-
abelson (BCR-ABL) kinase is complex and highly redundant and the
sum of these protein interactions is translated into the altered
phenotype of BCR-ABL-expressing chronic myeloid leukemia (CML)
cells, as well as of Philadelphia-positive (Ph+) acute lymphoblastic
leukemia (ALL) cells [1]. Signiﬁcant effort has been placed into
understanding the molecular mechanism of action of BCR-ABL
through the identiﬁcation of signaling pathways that are affected by
BCR-ABL tyrosine kinase activity. Numerous substrates and binding
partners of BCR-ABL have been identiﬁed and current efforts are
directed at linking these pathways to the speciﬁc pathologic defects
that characterize CML [1]. Despite the seemingly endless expansion of
the list of pathways activated byBCR-ABL and the increasing complexity
revealed in these pathways, all of the transforming functions of BCR-ABL
are dependent on its tyrosine kinase activity [2], which is speciﬁcally
inhibited by imatinib mesylate (Gleevec/Glivec, formerly STI571;
Novartis, Basel, Switzerland) [3]. Imatinib is a small molecular
inhibitor of BCR-ABL kinase and potently induces growth arrest and
apoptosis of BCR-ABL cells. The development of resistance to imatinibhas recently emerged as an important problem in patients with CML,
most often due to acquired mutations in the target kinase [4,5].
Different strategies have been implemented to overcome this
resistance, including the synthesis of new BCR-ABL ATP-competitive
or non-ATP-competitive inhibitors and multi-targeted kinase in-
hibitors [1]. An alternative approach is the use of other compounds
that do not bind directly to the BCR-ABL protein; instead, these
molecules act on several downstream pathways, regulated by or
linked in different ways to BCR-ABL, which leads to the malignant
transformation of the cells.
Insulin receptor substrate 1 (IRS1) is an intracellular signaling
adaptor protein that integrates and coordinates numerous biologically
key extracellular signals within the cell. First identiﬁed as a signaling
intermediate of the insulin receptor (IR), it is now clear that IRS1 is the
main substrate of the insulin-like grow factor 1 receptor (IGF-1R) and
alterations in IRS1 expression have been linked to diabetes and
speciﬁc cancers (hepatocellular, pancreatic, breast) [6]. IRS1 contains
multiple tyrosine phosphorylation sites, which during insulin stim-
ulation are phosphorylated and act as docking sites for multiple SH2-
containing proteins including p85, Grb2, Nck, Crk, Fyn, Syp and SHP2
[7]. Thus, insulin stimulation results in the activation of many
downstream pathways; the two best-studied being the phosphatidy-
linositol 3-kinase (PI3K)-Akt/mammalian target of rapamycin
(mTOR) and the Ras-mitogen-activated protein kinase (MAPK)
pathway, which includes the extracellular signal-regulated kinase
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in a number of biological events, including mitogenesis, cell motility,
metabolism, cytoskeletal organization, and cell survival [9]. There are
several YMXM motifs in the COOH-terminus on IRS1 that, when
phosphorylated by receptor tyrosine kinases (RTKs), bind to the SH2
domain of the p85 regulatory subunit of PI3K, resulting in the
downstream activation of numerous mitogenic and oncogenic
effectors, most notably Akt [7,9]. IRS1 binding to Grb2, which is
normally associated with mSOS (a guanine nucleotide exchange
factor), leads to stimulation of the classic MAPK pathway, which
includes the activation of the Ras/Erk cascade of kinases [10,11]. The
MAPK pathway is instrumental in cell growth, differentiation and
mutations in its downstream effectors are related to numerous
cancers [12]. In addition, IRS1 signaling involves the docking and
regulation of non-SH2 binding proteins and phosphorylated IRS1 has
been shown to bind to the loop domain of anti-apoptotic signaling
protein, BCL2, and enhance its anti-apoptotic activity [13].
Despite the fact that IRS1 has no intrinsic kinase activity and
requires upstream activators, many studies have shown that this
signaling adaptor is in itself oncogenic and can induce malignant
transformation [14–16]. Even though most of our knowledge
regarding the molecular functions of IRS1 protein has been derived
from studies in the insulin signaling system, there is evidence that this
protein participates in the BCR-ABL signaling pathway. IRS1 has been
previously described as being constitutively phosphorylated and
associated with BCR-ABL in K562 cells [17], and IRS1 expression was
found to be negatively correlated with survival in BCR-ABL positive
ALL patients, regardless of age and white blood cell count at diagnosis
[18]. Thus, new ﬁndings regarding themechanisms that link IRS1 with
BCR-ABL may be useful for developing novel therapeutic targets and
prognostic markers in BCR-ABL diseases. Hence, to further understand
the mechanisms of the action of IRS1 in the malignant process
through which BCR-ABL transforms cells, we have attempted to
identify the role of IRS1 in cell proliferation, clonogenicity, cell cycle
and apoptosis in K562 cells.
2. Materials and methods
2.1. Cell culture and reagent chemicals
K562 cells, which are known as a representative human CML cell
line, were obtained from ATCC, Philadelphia, PA, USA. Cells were
cultured in RPMI containing 10% fetal bovine serum (FBS) and
glutamine with penicillin/streptomycin and amphotericin B, and
maintained at 37 °C, 5% CO2. Imatinib mesylate was kindly provided
by Novartis Pharmaceuticals, Basel, Switzerland, and prepared as a
50 mM stock solution in dimethyl sulfoxide (Me2SO4; DMSO).
2.2. Transduction of lentivirus
K562 cells were transduced with lentivirus-mediated shRNA
nonspeciﬁc control (sc-108080) or lentivirus-mediated shRNA target-
ing IRS1 (sc-29376) from Santa Cruz Biotechnology (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and named shControl and shIRS1
cells, respectively. Brieﬂy, 2×105 cells were transducedwith lentiviral
by spinoculation at multiplicity of infection equal to 0.5 and selected
by puromycin (1.75 μg/mL).
2.3. Real-time RT-PCR analysis
Total RNA was extracted from cells using the TRIzol reagent,
according to the manufacturer's instructions (Invitrogen, Carlsbad,
CA, USA). The reverse transcription reaction was performed using
RevertAid™ First Strand cDNA Synthesis Kit, according to the
manufacturer's instructions (MBI Fermentas, St. Leon-Rot, Germany).
Expression of IRS1 mRNA was detected by Maxima Sybr green qPCRmaster mix, according to the manufacturer's instructions (MBI
Fermentas, St. Leon-Rot, Germany) in the ABI 7500 Sequence
Detection System (PE Applied-Biosystem) using speciﬁc primers:
forward 5′-TGACCATGCAGATGAGTTGTCC-3′, reverse 5′-CGCATGT-
CAGCATAGCTTACAG-3′; HPRT and β-actin were used as endogenous
controls and the primers respectively were: forward 5′-
GAACGTCTTGCTCGAGATGTGA-3′, reverse 5′-TCCAGCAGGTCAG-
CAAAGAAT-3′ and forward 5′-AGGCCAACCGCGAGAAG-3′, reverse
5′-ACAGCCTGGATAGCAACGTACA-3′. Relative levels of gene expres-
sion were quantiﬁed. The relative quantiﬁcation value was
calculated using the equation, 2−ΔΔCT [19]. A negative ‘no template
control’ was included for each primer pair. The dissociation
protocol was performed at the end of each run to check for non-
speciﬁc ampliﬁcation. Three replicas were run on the same plate for
each sample.
2.4. Western blot
Equal amounts of protein were used for total extracts or for
immunoprecipitation with speciﬁc antibodies followed by SDS-PAGE
and Western blot analysis with the indicated antibodies and ECL™
Western Blotting Analysis System (Amersham Pharmacia Biotech,
UK Ltd., Buckinghamshire, England) as described [17]. Monoclonal
antibodies against phospho(p)-tyrosine (sc-508), ABL (sc-23), p-ERK
(sc-7383), P70S6K (sc-8418), CRKL (sc-319), BAX (sc-20067) and
polyclonal antibodies against Actin (sc-1616), IRS-1 (sc-559), Akt 1/2
(sc-8312), p-P70S6K (sc-7984), BCL2 (sc-492), p-BAD (sc-7999) and
BAD (sc-943) were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Monoclonal antibodies against p-Akt (9271) and p-CRKL
(3181)were from Cell Signaling Technology (Cell Signaling, Danvers,
MA, USA) and Anti-ERK1/2 (13-6200) was from Zymed (Invitrogen,
Carlsbad, CA, USA). Blots were stripped and reprobed as necessary.
Quantitative analyses of the optical intensities protein bands were
determined with Scion Image software (ScionCorp, Frederick, MD,
USA) and normalized by actin for protein expression or total protein
for protein phosphorylation.
2.5. Methylthiazoletetrazolium (MTT) assay
Cell proliferation was measured by MTT assay. ShControl and
shIRS1 cells were serum-starved in 0.5% FBS for 12 h. A total of 5×104
cells per well were then plated in a 96-well plate in RPMI 10% FBS at
different concentrations of imatinib mesylate (0.1, 0.5 or 1 μM) for
48 h. In brief, 10 μl of a 5 mg/mL solution of MTT was added to the
wells and incubated at 37 °C for 4 h. The reaction was stopped by
using 100 μL of 0.1 N HCl in anhydrous isopropanol. Cell growth was
evaluated by measuring the absorbance at 570 nm, using an
automated plate reader. All conditions were tested in six replicates.
2.6. Colony formation assay
Colony formation was carried out in semisolid methyl cellulose
medium (0.5×103 cell/mL; MethoCult 4230; StemCell Technologies
Inc., Vancouver, BC, Canada). Colonies were detected after 8 days of
culture by adding 1 mg/mL of MTT reagent and scored by Image J
quantiﬁcation software (U.S. National Institutes of Health, Bethesda,
MD, USA). ShControl and shIRS1 cells were submitted to colony
formation assay in the presence or absence of imatinib mesylate (0.1,
0.5 or 1 μM). All conditions were tested in duplicate.
2.7. Cell cycle analysis
Cells were ﬁxed in 70% ethanol, for at least 2 h at 4 °C, and stained
with 20 μg/mL propidium iodide (PI) containing 10 μg/mL RNase A for
30 min at room temperature. Fluorescence cell analysis was per-
formed with a FACSCalibur (Becton–Dickinson, CA, USA). Resulting
1406 J.A. Machado-Neto et al. / Biochimica et Biophysica Acta 1813 (2011) 1404–1411DNA distributions were analyzed by Modiﬁt (Verify Software House
Inc., Topsham, ME, USA) for the proportions of cells in the phases of
the cell cycle.2.8. Assessment of apoptosis by Annexin-V and PI staining
ShControl and shIRS1 cells were seeded on 12-well plates and
treated with different concentrations of imatinib mesylate (0.1, 0.5 or
1 μM) for 48 h. Cells were then washed twice with ice cold PBS and
resuspended in binding buffer containing 1 μg/mL PI and 1 μg/mL FITC
labeled Annexin-V. All specimens were analyzed on a FACSCaliburFig. 1. Lentivirus-mediated shRNA targeting IRS1 effectively silenced IRS1 in K562 cells. (A an
mRNA expression levels of IRS1 were normalized by HPRT and β-actin endogenous contro
triplicate (C) Western blotting analysis of shControl and shIRS1 total cell extracts. The memb
for equal sample loading, and developed with the ECL Western Blotting Analysis System. (
immunoprecipitated (IP) with anti-IRS1 antibody and immunoblotted (IB) with anti-pho
shControl and shIRS1 cells were blotted with antibodies against p-Tyr and were reprobed wi
of fold change in mean±SD of band intensity, of 3 independent experiments, relative to
*Pb0.05, Student t test.after incubation for 15 min at room temperature in a light-protected
area. Ten thousand events were acquired for each sample.
2.9. Caspase-3 activity assay
Caspase-3 activity was measured as recommended by the
manufacturer (Calbiochem, La Jolla, CA, USA). ShControl and shIRS1
cells were seeded in 6-well plate and treated with different
concentrations of imatinib mesylate (0.1, 0.5 or 1 μM) for 48 h. Cells
(106 cells/mL) were incubated with FITC-DEVD-FMK (1:300) in non-
supplemented medium for 40 min at 37 °C in a humidiﬁed atmo-
sphere of 5% CO2. Cells were then washed, resuspended in non-d B) Quantitative expression of IRS1mRNA in shIRS1 cells relative to the shControl cells.
l, as indicated. Results were analyzed using 2−ΔΔCT. Experiments were performed in
rane was blotted with antibodies against IRS1 (185 kDa) or actin (42 kDa), as a control
D) Lysates from shControl and shIRS1 cells containing equal amounts of protein were
sho-tyrosine (p-Tyr) antibody. (E) Western blotting of total cell extracts from K562
th the antibody against actin. In ﬁgures C and D, the bar graphs represent the percentage
control. The controls were set as 100% in each experiment (Scion Imagine software).
Fig. 3. IRS1 silencing reduces clonogenicity in K562 cells. Colonies containing viable
cells were detected by MTT after 8 days of incubation of shIRS1 or shControl cells with
or without imatinib mesylate (0.1; 0.5 or 1 μM). Values are expressed in percentage,
and normalized to the shControl value set as 100%. Results are shown as mean±SD of 3
independent experiments performed in duplicate. *P=0.0007; **P=0.0008, Student t
test.
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1 channel.
2.10. Statistical analysis
Statistical analysis was performed using GraphPad Instat 3
(GraphPad Software, Inc., San. Diego, CA, USA). Data were expressed
as the mean±standard deviation (SD). For comparisons, an appro-
priate Student's t-test or Mann–Whitney test was used. The level of
signiﬁcance was set at Pb0.05.
3. Results
3.1. Efﬁcient downregulation of IRS1 expression and its phosporylation in
K562 cells after lentivirus shRNA transduction
To examine the effects of IRS1 silencing on a CML cell model, K562
cells were stably transduced with lentivirus-mediated shRNA target-
ing IRS1 or an appropriate control. After selection by puromycin,
mRNA and proteins levels of IRS1 were determined by real time RT-
PCR and Western blot. A signiﬁcant reduction in IRS1 mRNA (by 84±
2%) and protein (by 74±9%) levels was observed in shIRS1 when
compared with shControl (Fig. 1A–C). Since the signaling through
IRS1 is regulated not only at the expression level, but at the
phosphorylation level as well, it was important to conﬁrm whether
IRS1 silencing also resulted in the downregulation of its own
phosphorylation. Similarly to what was observed with IRS1 expres-
sion, IRS1 phosphorylation was signiﬁcantly decreased in shIRS1 cells
when compared with shControl cells (by 45±6%) (Fig. 1D). We then
veriﬁed whether IRS1 silencing interfered with the phosphorylation
levels of other phosphotyrosine-containing proteins, and found that a
reduced tyrosine phosphorylation of proteins was observed in a totalFig. 2. IRS1 silencing reduces proliferation in K562 cells. (A) Cell proliferation was
determined by MTT assay after 48 h of incubation of shIRS1 or shControl cells with or
without imatinib mesylate (0.1; 0.5 or 1 μM) and normalized by untreated shControl
cells. Results are shown as mean±SD of six replicate and it is representative of 3
independent experiments. *P=0.0002; Mann–Whitney test. (B) Equal amounts of
proteins from K562 cells treated or not with imatinib mesylate (0.1; 0.5 or 1 μM) for
48 h were immunoprecipitated (IP) with anti-IRS1 antibody and immunoblotted (IB)
with anti-phosho-tyrosine (p-Tyr) antibody.protein extract from the shIRS1 cells when compared with shControl
cells (Fig. 1E).
3.2. IRS1 silencing signiﬁcantly reduces proliferation in K562 cells
The effect of IRS1 silencing on the proliferation of K562 cells was
accessed by MTT assay. After 48 h of culture, proliferation was
signiﬁcantly reduced in shIRS1 cells when compared with shControl
cells (inhibition rate=40±5%; P=0.002) (Fig. 2A). This result
prompted us to observe for the effects of IRS1 silencing, concomitant
with imatinib mesylate treatment in K562 cells, as this small-
molecule is capable of inhibiting IRS1 phosphorylation, as previously
described [17] and as shown in Fig. 2B, and presents remarkable
clinical activity in patients with CML [1]. As expected, after 48 h of
treatment with 0.1, 0.5 or 1 μM of imatinib mesylate, we observed a
dose-response effect in reducing proliferation in K562 cells. When
cells were exposed to 0.1 μM imatinib, the ability of IRS1 silencing to
reduce proliferation was evident compared to shControl (P=0.002).
However, no synergism was observed between imatinib treatment
and IRS1 silencing (Fig. 2A). Thus, it was clear that although IRS1
knockdown reduced the proliferation of K562 cells, no cumulative
effect was observed with imatinib treatment and IRS1 silencing.
3.3. IRS1 silencing inhibits colony formation of K562 cells
Colony formationwas used to determine whether IRS1 silencing in
K562 cells altered clonal growth. ShControl and shIRS1 cells were
suspended in a methylcellulose medium and assessed for their ability
to form colonies. A signiﬁcant decrease of 61±14% in the number of
colonies was observed in shIRS1, as compared to shControl cells
(P=0.0007; Fig. 3). Imatinib treatment resulted in a dose dependent
inhibition of K562 cell colony formation. At the lowest dose of
imatinib (0.1 μM), we still observed the effect of IRS1 silencing onTable 1
Effect of IRS1 silencing on the cell cycle phases of K562 cells.
K562 cell Cell cycle phase (%)
G0/G1 S G2/M
shControl 39.11±7.0 39.11±11.9 21.78±5.7
shIRS1 45.85±5.2* 29.18±9.3* 24.98±4.2
Cell cycle phases detected by ﬂow cytometry. Results are expressed as the percentage of
total cells. Three independent experiments were performed and mean±SD are
presented, *Pb0.05.
Fig. 4. Knockdown of IRS1 does not affect apoptosis in K562 cells. Apoptosis was detected by ﬂow cytometry in shControl and shIRS1 cells with or without imatinib mesylate (0.1; 0.5
or 1 μM) using Annexin-V/PI staining method. Figures indicate the relative number of cell (%) in the quadrants. The lower right quadrant contains the apoptotic (Annexin-V+/PI−)
population. Results are representative of three independent experiments.
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again, no synergistic effect was observed between the imatinib
mesylate treatment and IRS1 silencing. These ﬁndings indicated that
IRS1 knockdown in K562 cells resulted in a clonogenic reduction.
3.4. IRS1 silencing induces cell cycle delay at the G0/G1 phase K562 cells
Flow cytometry analyses revealed a signiﬁcant accumulation of
shIRS1 cells at G0/G1 phase of the cell cycle followed by a decreasing
number of cells in the S phase, when compared with shControl cells
(Table 1). IRS1 silencing in K562 cells then induced a G0/G1 block and
prevented cells from entering the S phase, which correlated with
decreased cell proliferation and colony formation.
3.5. Apoptosis is unaffected by IRS1 knockdown
To investigate the effects of IRS1 silencing on cell death, the rate of
apoptosis was evaluated by ﬂow cytometry after cell incubation withFig. 5. Knockdown of IRS1 does not change caspase-3 activity in K562 cells. Caspase-3
activity was measured by ﬂow cytometry in shControl and shIRS1 cells treated or not
with imatinib mesylate (0.1; 0.5 or 1 μM) for 48 h. Bar graphs represent the mean±SD
of three independent experiments.annexin-V/PI, and also with FITC-DEVD-FMK for measuring caspase 3
activity. No difference in the percentage of apoptosis, either by
Anexin-V/PI or caspase 3 assay, was observed in shIRS1 cells when
compared with shControl cells (Figs. 4 and 5 respectively). Imatinib
mesylate treatment, together with IRS1 knockdown, showed no
cumulative effects, although drug treatment alone effectively induced
apoptosis and caspase 3 activity in a dose-response manner (Figs. 4
and 5, respectively).
3.6. IRS1 silencing results in downregulation of the Akt/mTOR and MAPK
pathways
Of the IRS1 intracellular signaling pathways, two main pathways,
the PI3K-Akt/mTOR and the Ras/MAPK cascades, have been previously
shown to be activated by IRS1 [6]. Thus, it may be debated as to
whether these pathways are downregulated after IRS1 silencing in
BCR-ABL cells.
Akt and P70S6K phosphorylation were signiﬁcantly decreased in
shIRS1 cells, when compared with shControl cells; showing a
reduction of 55±3% and 59±14%, Pb0.05, respectively (densitom-
etry quantiﬁcation and normalization for total protein of three
independent experiments) (Fig. 6A and B). There was a similar
signiﬁcant decrease in ERK1/2 phosphorylation in shIRS1 cells when
compared with shControl cells (reduction of 67±11%, P=0.0083)
(Fig. 6C). The expression level of the anti-apoptotic BCL2, the pro-
apoptotic BAX protein, and the phosphorylation levels of the pro-
apoptotic BAD protein demonstrated no differences between shIRS1
and shControl cells (Fig. 7). The downregulation in the phosphory-
lation of Akt, P70S6K and ERK1/2 proteins in shIRS1 cells was in
agreement with lower rates of cell proliferation upon IRS1 silencing.
Nevertheless, proteins involved in survival signaling along the same
pathway as BCL2, BAX and BADwere not modulated by IRS1 silencing,
corroborating our ﬁndings in apoptosis.
3.7. IRS1 silencing does not affect BCR-ABL and CRKL phosphorylation
We checked if IRS1 silencing would change the phosphorylation
status of BCR-ABL and CRKL, a protein downstream to BCR-ABL. No
modulation in BCR-ABL or CRKL phosphorylation levels was observed
in shIRS1 cells, when compared with shControl cells (Fig. 8).
Fig. 6. IRS1 silencing decreases phosphorylation of Akt, P70S6K and ERK in K562 cells. Western blotting analysis of shControl and shIRS1 cells for the expression of phospho-Akt (A),
phospho-P70S6K (B) and phospho-ERK 1/2 (C); membranes were reprobed with the antibody for detection of the respective total protein. Bars represent densitometric analysis of
blots as mean±SD of three independent experiments versus shControl, set as 100%. P*b0.05 Student t test.
Fig. 7. Knockdown of IRS1 does not change BLC2 and BAX expression and BAD phosphorylation inK562 cells.Western blotting analysis of shControl and shIRS1 cells for BCL2 (A), BAX (B),
and phospho-BAD (C) expression. Anti-actin (A and B) or anti-total BAD (C) was used as loading control as depicted. Bars represent densitometric analysis of blots as mean±SD of three
independent experiments versus shControl, set as 100%. P*b0.05 Student t test.
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Herein, we analyzed the effect of IRS1 silencing, by shRNA-
lentiviral delivery, in K562 cells, a well established CML cell line thatFig. 8. Knockdown of IRS1 does not affect BCR-ABL and CRKL phosphorylation in K562 cells.
immunoprecipitated (IP) with anti-ABL antibody and immunoblotted (IB) with anti-phosho
and normalized to the total CRKL expression. Densitometric analysis of the phosphorylate
densitometric quantiﬁcation of blots as mean±SD of three independent experiments versupresents the BCR-ABL chimeric oncogene, known as the Philadelphia
translocation. Our results showed that IRS1 silencing with conse-
quently decreased IRS1 phosphorylation, decreased cell proliferation
and clonogenicity in K562 cells, which correlates with the delay of(A) Lysates from shControl and shIRS1 cells containing equal amounts of protein were
-tyrosine (p-Tyr) antibody. (B) Total cell extracts were blotted with anti-phosho-CRKL
d protein relative to total protein was performed for each experiment. Bars represent
s shControl, set as 100%.
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cycle. These ﬁndings are in agreementwith those of other authors that
have previously described the role of IRS1 in proliferation and in
somatic growth regulation. For instance, IRS1-deﬁcient mice were
approximately 30% smaller than the wild-type littermates [20,21].
Nevertheless, overexpression of IRS1 in the mouse mammary gland
resulted in hyperplasia and tumorigenesis [22]. The oncogenic role of
IRS1 and its ability to induce malignant transformation have been
previously described [15,23]. The inhibition of IRS1 with siRNA
strategies has been shown to represent a good target for controlling
proliferation in prostate, breast and hepatoma cancer cell lines
[22,24–27]. Interestingly, the inhibition of the IGF-1R, a tyrosine
kinase receptor upstream to IRS1, decreased the clonogenicity of
leukemic progenitors and the proliferation of PI3K activated acute
myeloid leukemia cells [28]. Our results provide new evidence that
IRS1 also plays a role in proliferation in BCR-ABL cells.
To further clarify the signaling pathway inhibited by IRS1
knockdown in K562 cells, we checked the activation status of Akt
and P70S6K, essential proteins of the Akt/mTOR pathway, and ERK1/2,
one of theMAPK proteins. These signaling pathways regulate a variety
of cellular activities including proliferation, differentiation, survival,
and death [29,30]. IRS1 silencing in K562 cells resulted in a decrease of
Akt, P70S6K and ERK1/2 phosphorylation, indicating a downregula-
tion in Akt/mTOR andMAPK pathway, respectively. The role of IRS1 in
the activation of Akt/mTOR andMAPK pathways is well known [7,8]. A
previous study by our group showed that IRS1 associated and
activated PI3K in K562 cells and also associated with Grb2 [17],
justifying our current ﬁndings demonstrating that IRS1 knockdown
decreases Akt and P70S6K phosphorylation, possibly through down-
regulation of PI3K signaling, in addition to the decrease of ERK1/2
phosphorylation, possibly through the IRS1/Grb2 association that
ultimately links IRS1 to the Ras signaling cascade. Taken together,
these ﬁndings indicate that the inhibition of IRS1 results in decreased
proliferation and clonogenicity of cells and in the inhibition of Akt,
P70S6K and ERK1/2 phosphorylation. Moreover, a signiﬁcant accu-
mulation of cells in the G0/G1 phase of the cell cycle, followed by a
decreased number of cells in the S phase was observed. These are
interesting ﬁndings, which are supported by previous evidence that
the activation of P70S6K regulates a wide range of cellular processes
including protein synthesis, progression of G1 towards the S phase of
the cell cycle [31,32]. Furthermore, inhibition of P70S6K blocks
proliferation and induces G1 cell cycle arrest without affecting
apoptosis in pancreatic cancer cells [33].
In BCR-ABL cells, IRS1 silencing did not affect apoptosis, despite
the inhibition of Akt phosphorylation. The most established function
of Akt in mammalian cells is inhibition of apoptosis, which may
contribute to the genesis of cancer. However, this function alone is
not likely to be sufﬁcient to explain the frequent activation of Akt in
human cancer. Genetic evidence that Akt is required for cell
proliferation, normal G1/S phase transition and oncogenic transfor-
mation, regardless of its antiapoptotic function, has been previously
described [34]. Increased activation of Akt has been associated with
increased cell proliferation in cancer [34] and with poor prognosis in
acute leukemia [35]. Indeed, it is known that the speciﬁc inhibition of
PI3K activity decreases AML cell proliferation without inducing
apoptosis [36,37] and inhibition of IGF-1R blocks proliferation;
without affecting apoptosis in AML bone marrow samples [28]. The
observation that apoptosis was not modulated by IRS1 silencing is in
agreement with the non-modulation of proteins involved in
apoptosis, thus no changes were observed in phosphorylation of
BAD and in the expression of BCL2 and BAX. These results also
indicate that activation of multiple molecules and signaling path-
ways downstream to BCR-ABL leads to the malignant transformation
of the cells and is responsible for the leukemia phenotype, suggesting
that multi-target protein inhibitors are necessary to control the
disease.We showed that there were no cumulative effects of IRS1 silencing
and imatinib mesylate treatment on cell proliferation and colony
formation, neither in apoptosis, in K562 cells. As previously reported,
IRS1 is associatedwith BCR-ABL in K562 cells [17], and the ﬁnding that
IRS1 silencing does not modulate the phosphorylation of BCR-ABL and
CRKL proteins indicates that IRS1 acts as a downstream adaptor
protein to the BCR-ABL pathway. In this context, the inhibition of BCR-
ABL by imatinib treatment may overcome the effect of IRS1 silencing
and be highly efﬁcient in reducing proliferation and clonogenicity and
in inducing apoptosis in K562 cells. Nevertheless, the inhibition of
IRS1 alone, as observed in cells not exposed to imatinib, is capable of
inhibiting proliferation, and clonogenicity and promotes to cell cycle
arrest in BCR-ABL cells. The same effects were also observed in IRS1
knockdown cells exposed to a low dose of imatinib (0.1 μM). These
ﬁndings draw attention to the possibility of controlling cell prolifer-
ation in BCR-ABL-positive cells by targeting other proteins, in addition
to BCR-ABL.
5. Conclusions
Tyrosine kinase inhibitors, such as imatinib mesylate, have
rationally been designed as ﬁrst-line therapies for CML. However,
the success of these inhibitors has been tempered by the emergence of
resistance to the treatment, causing recurrence of CML. Thus, the
identiﬁcation of new target genes/pathways involved in the patho-
physiology of CML disease is critical. We demonstrated, for the ﬁrst
time, that IRS1 silencing results in a decrease on proliferation and
downregulation of the Akt/mTOR and MAPK pathways in the K562
cell line. These novel ﬁndings open the door to future research where
studies using other CML cell lines, and patient cells, in addition to in
vivo growth of K562 shIRS1 cells in a xenogeneic model could provide
further evidence for the role of IRS1 in BCR-ABL-mediated tumori-
genesis and consequently, validate IRS1 as a target gene for treatment
of Imatinib resistant CML. However, target IRS1 as a complementary
therapeutic regimen to CML appears to be a reasonable measure, as
IGF-1R has already become a target for anticancer therapy in several
tumor types [38–40].
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